For people with vitiligo and their caregivers
What this page helps you do
Prepare for a treatment review when your current plan may no longer fit. Progress, reactions, daily effort, access, new patches, or changing goals may prompt that review.
- Your task
- Organize the information, priorities, and next review needed for a real-world decision.
- The clinician boundary
- Diagnosis, assessment of activity and body sites, prescribing, monitoring, and personalized treatment decisions belong to a qualified clinician.
How do I know it is time to review the plan?
It may be time to review your plan when any of these things happen: Evidence Evidence
- You reach the review point you agreed on.
- Your skin seems to change.
- Your progress does not match the goal.
- You have a reaction.
- The routine is too hard to sustain.
- Your access to care changes.
- Your priorities change.
Why this item matters
Vitiligo decisions are built around clinical pattern and activity, body site, prior care, health context, patient goals, burden, and follow-up. Revisiting a choice is part of shared decision-making rather than proof that you did something wrong.
What should I bring to make the review useful?
Bring the treatment record you actually have. Include what you used, skipped, or held. Add changes, reactions, new areas, access problems, and comparable photos when available. An incomplete record is more useful than false certainty from memory. Evidence Evidence
Why this item matters
Consistently framed photographs and dated observations can support a clinical conversation. Treatment burden, life impact, and practical barriers also belong beside visible skin change.
When should I switch from a topical treatment to narrowband UVB?
There is no universal calendar or result that tells everyone to switch. Compare the current goal and evidence with body-area expectations, daily effort, risks, and access. Ask whether light would replace the exact cream or be coordinated with it. Evidence Evidence Evidence
Why this item matters
Guidelines include topical and light-based options and support individualized, shared decisions. Selected combinations have evidence, but that does not create a general sequence for every medicine or patch.
Do burden, cost, mood, and daily life count as reasons to change course?
Yes, they belong in the decision even when a treatment makes medical sense. A plan may stop fitting your life. Travel, time, privacy, cost, discomfort, uncertainty, emotional strain, and daily work can all change the balance. Evidence Evidence
Why this item matters
Guidelines recognize quality of life and patient priorities as part of treatment choice. Choosing a lower-burden path, camouflage, support, or no active treatment can be a deliberate decision.
What if I have a reaction, a new medicine, or a health change?
Record what happened and contact the responsible clinical team using their plan. Do not adjust a prescription or light setting without their instructions. New medicines, pregnancy, illness, eye concerns, or changing reactions may require a fresh safety review. Evidence Evidence
Why this item matters
Prescription labels and phototherapy guidance contain treatment-specific warnings and precautions. Coordinated review matters when more than one clinician or treatment is involved.
Questions that can change the next decision
- For your clinicianWho is responsible for reconciling all of my medicines and light treatment?Saving keeps this on your device and needs JavaScript, which is off in this browser.
- For your clinicianWhich changes need a message, prompt call, or urgent care?Saving keeps this on your device and needs JavaScript, which is off in this browser.
Applicability check
Who was studied?
These fields show what the cited evidence reports about the people and body sites behind outcome or safety claims. “Not reported” means the reviewed source omitted the field; “Pending exact source review” means SteadySkin has not made that determination yet.
Record what happened and contact the responsible clinical team using their plan. Do not adjust a prescription or light setting without their instructions. New medicines, pregnancy, illness, eye concerns, or changing reactions may require a fresh safety review.
- Age range
- Pending exact source review
- Condition subtype
- Pending exact source review
- Severity or extent
- Pending exact source review
- Sample size
- Pending exact source review
- Geography and care setting
- Pending exact source review
- Skin tone or phototype
- Pending exact source review
- Race
- Pending exact source review
- Ethnicity
- Pending exact source review
- Body sites
- Pending exact source review
What that means for this page: This is explicitly gated as a safety claim, but exact population extraction is still pending. It cannot publish or support an estimate of individual risk until that review is complete.
Evidence behind this page
Sources
Each evidence badge opens the source and its limits. The full list stays available here.
- Journal of the European Academy of Dermatology and VenereologyRegulatory / guideline · not independentRelevant relationship disclosed
- Published
- 2023-09-15
- SteadySkin last checked
- 2026-07-31
What this source can and cannot tell you
Why the independence label says this: The journal is the publisher. This label refers to extensive author relationships disclosed for the recommendation, not to the journal itself.
What this source supports
Supports an expert-consensus map of established, off-label and developing Vitiligo treatment categories and makes clear that research is continuing.
What it does not support
It is an international consensus with extensive author relationships, not independent comparative proof, current U.S. regulatory status for every option or a personal treatment sequence.
Automated draft claim mapping withheld from reader-facing evidence details until clinical or editorial review is recorded. This page is not yet approved for indexing.
- JAMA Dermatology (Ezzedine K, et al.)Supporting research · not independentIndependence not established
- Published
- 2024-10-30
- SteadySkin last checked
- 2026-07-31
What this source can and cannot tell you
What this source supports
Supports defined research use and psychometric evaluation of facial and total VASI measures and the need to interpret score change in the studied context.
What it does not support
The analysis used sponsor trial data and included AbbVie authors; it does not establish one personally meaningful outcome, validate untrained home scoring or provide a treatment-change rule.
Automated draft claim mapping withheld from reader-facing evidence details until clinical or editorial review is recorded. This page is not yet approved for indexing.
- U.S. Food and Drug AdministrationRegulatory / guideline · not independentIndependence not established
- Published
- 2025-09-18
- SteadySkin last checked
- 2026-08-06
What this source can and cannot tell you
What this source supports
Supports the defined US nonsegmental-vitiligo indication, limitations of use, boxed warnings, skin-cancer and ultraviolet precautions, and clinical-study labeling.
What it does not support
It does not guarantee benefit, establish suitability beyond the labeled population or authorize adding phototherapy.
Automated draft claim mapping withheld from reader-facing evidence details until clinical or editorial review is recorded. This page is not yet approved for indexing.
- British Journal of Dermatology (Thomas KS, et al.)Clinical research · independentIndependent source
- Published
- 2020-12-28
- SteadySkin last checked
- 2026-07-31
What this source can and cannot tell you
What this source supports
Supports a group-level benefit for the exact supervised topical-corticosteroid and home handheld-light combination studied in active limited vitiligo, alongside minority success, reactions and limited maintenance after treatment ended.
What it does not support
It does not create a general home plan, support other product-device combinations or predict an individual result.
Automated draft claim mapping withheld from reader-facing evidence details until clinical or editorial review is recorded. This page is not yet approved for indexing.
- Journal of the European Academy of Dermatology and VenereologyRegulatory / guideline · not independentRelevant relationship disclosed
- Published
- 2023-09-25
- SteadySkin last checked
- 2026-07-31
What this source can and cannot tell you
Why the independence label says this: The journal is the publisher. This label refers to extensive author relationships disclosed for the recommendation, not to the journal itself.
What this source supports
It supports current expert-consensus terminology, clinical assessment, disease-activity evaluation, treatment-goal discussion, and shared decision-making.
What it does not support
It is not independent comparative proof. It cannot diagnose a reader from a description or photograph.
Automated draft claim mapping withheld from reader-facing evidence details until clinical or editorial review is recorded. This page is not yet approved for indexing.
- British Journal of Dermatology (Eleftheriadou V, et al.)Regulatory / guideline · independentIndependent source
- Published
- 2022-01-01
- SteadySkin last checked
- 2026-07-31
What this source can and cannot tell you
What this source supports
Supports the clinical history and assessment domains, evaluation of associated autoimmune conditions, its recommendation for thyroid function and antithyroid antibody screening, current classification context, treatment-option map, psychosocial assessment, medical photography and the limits of pediatric evidence.
What it does not support
It was designed for UK care and reviewed literature through May 2019; it does not establish a universal testing plan, prescribe an individual plan, or establish current US labeling or coverage.
Automated draft claim mapping withheld from reader-facing evidence details until clinical or editorial review is recorded. This page is not yet approved for indexing.
- British Journal of Dermatology (Goulden V, et al.)Regulatory / guideline · independentIndependent source
- Published
- 2022-09-01
- SteadySkin last checked
- 2026-07-29
What this source can and cannot tell you
What this source supports
It supports that traditional NB-UVB fluorescent lamps emit a narrow UVB band peaking around 311 nanometres, plus clinical uses, comparisons with other ultraviolet treatments, and safety boundaries including sunburn-type reactions.
What it does not support
It does not provide a personal treatment plan or establish any home-use setting. SteadySkin never reproduces its treatment schedules.
Automated draft claim mapping withheld from reader-facing evidence details until clinical or editorial review is recorded. This page is not yet approved for indexing.